However, in both KRAS mutant and KRAS wild type CCA mouse models, MEK inhibitors were able to repress tumor growth, again suggesting that upstream activating mutations do not always predict treatment outcomes (Dong et al. 2018; Wang et al. 2019). The gene discussed is KRAS; the disease is neoplasm.